A Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers

NCT03762031 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: GC4711 30mg
DRUG: GC4711 60mg
DRUG: GC4711 90mg
DRUG: GC4711 120mg
DRUG: Placebo
DRUG: GC4711 75mg
DRUG: GC4711 105mg

Sponsor

Galera Therapeutics, Inc.